Outcomes after hepatic resection and subsequent multimodal treatment of recurrence for multifocal hepatocellular carcinoma

British Journal of Surgery

Volumn 100, Issue 11, 2013, Pages 1516-1522

  Kim, P T W ^a   Jang, J H ^a   Atenafu, E G ^b   Fischer, S ^a   Greig, P D ^a   McGilvray, I D ^a   Wei, A C ^a   Gallinger, S ^a   Cleary, S P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; DISEASE FREE SURVIVAL; EVALUATION STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; LIVER TUMOR; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; STATISTICS; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84883482829     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9263     Document Type: Article

References (24)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
3. Llovet JM, Bruix J,. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
4. Forner A, Llovet JM, Bruix J,. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
5. Cheung TT, Ng KK, Chok KS, Chan SC, Poon RT, Lo CM, et al., Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes. World J Gastroenterol 2010; 16: 3056-3062.
6. Choi D, Lim HK, Joh JW, Kim SJ, Kim MJ, Rhim H, et al., Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol 2007; 14: 3510-3518.
7. DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, et al., Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011; 253: 166-172.
8. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
9. Shah SA, Wei AC, Cleary SP, Yang I, McGilvray ID, Gallinger S, et al., Prognosis and results after resection of very large (> or =10 cm) hepatocellular carcinoma. J Gastrointest Surg 2007; 11: 589-595.
10. Dindo D, Demartines N, Clavien PA,. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
11. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al., Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011; 149: 713-724.
12. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
13. Pepe MS, Mori M,. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993; 12: 737-751.
14. Pons F, Varela M, Llovet JM,. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005; 7: 35-41.
15. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al., Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691.
16. Wu CC, Cheng SB, Ho WM, Chen JT, Liu TJ, P'Eng FK,. Liver resection for hepatocellular carcinoma in patients with cirrhosis. Br J Surg 2005; 92: 348-355.
17. Ramacciato G, Mercantini P, Petrucciani N, Ravaioli M, Cucchetti A, Del Gaudio M, et al., Does surgical resection have a role in the treatment of large or multinodular hepatocellular carcinoma? Am Surg 2010; 76: 1189-1197.
18. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al., Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916.
19. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, et al., Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20: 1527-1536.
20. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al., Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
21. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al., Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
22. Molinari M, Kachura JR, Dixon E, Rajan DK, Hayeems EB, Asch MR, et al., Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin Oncol (R Coll Radiol) 2006; 18: 684-692.
23. Liu CL, Fan ST, Lo CM, Ng IO, Poon RT, Wong J,. Hepatic resection for bilobar hepatocellular carcinoma: is it justified? Arch Surg 2003; 138: 100-104.
24. Raut CP, Izzo F, Marra P, Ellis LM, Vauthey JN, Cremona F, et al., Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol 2005; 12: 616-628.